Compare Brookfield Infrastructure Partners LP (BIP) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Citius Pharmaceuticals Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $39 (market cap $18.10B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Brookfield Infrastructure Partners LP is far larger — about 904.5× Citius Pharmaceuticals Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BIP | CTXR | |
|---|---|---|
Market Cap | $18.10B | $20.01M |
Sector | Industrials | Health |
52-Week High | $42.62 | $1.82 |
52-Week Low | $29.81 | $0.48 |
Enterprise Value | $77.05B | $16.23M |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
